Moderna, Inc. (MRNA) stock surged more than 5% in pre-market trading on Tuesday, following the announcement that the company secured a $590 million award from the U.S. government to accelerate the development of its bird flu vaccine candidate, mRNA-1018.
The funding from the Department of Health and Human Services (HHS) comes as the U.S. doubles down on efforts to tackle the increasing number of bird flu infections in humans. Moderna stated that it is preparing to advance mRNA-1018 into late-stage clinical trials based on promising preliminary data from an early-to-mid stage study.
The news of the substantial government award for Moderna's pandemic flu vaccine program was welcomed by investors, driving the biotech company's stock higher in pre-market trading. Analysts believe that the successful development and commercialization of mRNA-1018 could provide a significant revenue stream for Moderna in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.